ClinicalTrials.gg
Status unknownNCT01500850Updated Dec 29, 2011

Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use

A Phase 4 interventional study of nph insulin and human insulin in Insulin-requiring Type 2 Diabetes Mellitus, sponsored by ikfe-CRO GmbH. Status unknown at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-12-29.

Sponsored by ikfe-CRO GmbH · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2011), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 — none open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 2.

Planned enrollment
29th of 49
60 · median 129
Started
2011
with 2 others
Phase 4
7 of 49
none open now
Registered
36th of 49
by date

Among the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2, this one is the 29th largest by planned enrollment, is one of 3 that started in 2011, is one of 7 in phase 4, and was the 36th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About Insulin, Regular, Human

Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The aim of this study is to observe changes in cardiovascular biomarkers during treatment with Lantus in patients with Type 2 Diabetes mellitus.

Read the detailed description
  • Phase IV
  • Indication: Diabetes mellitus Type 2
  • Primary objective:

To compare fasting intact proinsulin secretion at the beginning and after a 24 week treatment period.

  • Secondary objectives: To evaluate changes in the parameters
  • insulin,
  • glucose,
  • intact proinsulin (after a glucose challenge),
  • hsCRP,
  • adiponectin,
  • MMP-9,
  • HbA1c,
  • weight

after 24 weeks of treatment.

To investigate the changes of

  • glucose,
  • intact proinsulin,
  • hsCRP,
  • adiponectin,
  • HbA1c
  • weight

between visit 2 (baseline), visit 6 (12 weeks) and visit 8 (final visit after 24 weeks).

To investigate the number of patients with normal values for parameters hsCRP, adiponectin, and intact proinsulin after 24 weeks of treatment (responder rates).

-Primary efficacy variable: Fasting intact proinsulin concentration at timepoint Visit 2 (Baseline) and Visit 8 (after 24 week treatment)

-Secondary efficacy variables: All secondary parameters will be assessed after 24 weeks of treatment and compared versus baseline assessment.

  • Weight
  • hsCRP
  • Adiponectin
  • MMP-9
  • OGTT parameters (insulin, intact proinsulin, glucose at time point 0, 60 and 120 minutes after 24 weeks
  • HOMA-IR score
  • HbA1c

Additionally the following parameters will be assessed at visit 6 and will be compared with visit 2 and visit 8:

  • Weight
  • hsCRP
  • Adiponectin
  • Fasting intact Proinsulin
  • Glucose
  • HbA1c
  • Safety Variables:
  • Adverse Events
  • Hypoglycaemic events

Medication/Dosage:

Insulin glargine, dose individually adapted to reach treatment goal (FBG ≤ 100 mg/dL)NPH Insulin, dose individually adapted to reach treatment goal (FBG ≤ 100 mg/dL)Insulin glulisine, dose individually adapted to reach treatment goal (FBG ≤ 100 mg/dL)Human Insulin, dose individually adapted to reach treatment goal (FBG ≤ 100 mg/dL)

-Study Duration: Duration of study participation for one patient is approximately 26 weeks. Overall total duration of the study is approximately 10 months.

Design:

This is a randomized in four arms, open-label, multi-center study. Population Patients with Type 2 Diabetes mellitus, Sample Size n = 60 (15 per arm)

03

Conditions studied

  • Insulin-requiring Type 2 Diabetes Mellitus

Keywords

  • Type 2 Diabetes mellitus
  • NPH insulin
  • Insulin Glargine
  • cardiovascular biomarkers
  • hsCRP, adiponectin
  • intact proinsulin
  • cardiovascular risk
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Give written .
  • Patient consents that his/her family physician/diabetologist will be informed of trial participation
  • Type-2 diabetes mellitus ≥ 1 year of diagnosis (male and female)
  • Experienced in self blood glucose measurement for ≥ 3 months.
  • ≤ 9% and >6,5%
  • > 30 kg/m²
  • Age ≥ 18 years
  • Waist circumference > 88 cm (female) and > 102 cm (male)
  • NPH insulin treatment plus 1 or 2 OAD (except TZD)

Exclusion criteria

Exclusion Criteria:

  • History of drug or alcohol abuse within the last five years prior to screening
  • Anamnestic history of to the study drugs (or any component of the study drug) or to drugs with similar chemical structures
  • History of severe or multiple allergies
  • Treatment with any other drug within 3 months prior to screening
  • Progressive fatal disease
  • History of significant cardiovascular, respiratory, gastrointestinal, hepatic (ALAT and/or ASAT > 3 times the normal reference range), renal (creatinine > 1.3 mg/dl in women and >1.6 mg/dl in men), neurological, psychiatric and/or hematological disease as judged by the investigator
  • Pregnant or lactating women
  • Sexually active women of not consistently and correctly practicing by implants, injectables, combined oral contraceptives, hormonal intrauterine devices (IUDs), sexual abstinence or vasectomized partner
  • Treatment with GLP1-analog or Thiazolidinediones (TZD)
  • hsCRP > 10 mg/l (by rapid test at screening visit).
  • Lack of compliance or other similar reason that, according to investigator, precludes satisfactory participation in the study
  • Type 1 Diabetes mellitus
  • Patients already treated with intensified conventional insulin therapy.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    NPH insulin + insulin glulisine

    Patients will be randomized to be treated with NPH insulin + Insulin Glulisine for 24 weeks.

    Drug: nph insulin · Drug: Insulin glulisine

  • Active comparator
    NPH insulin + human insulin

    Patients will be randomized to be treated with NPH insulin + human insulin for 24 weeks.

    Drug: human insulin

  • Experimental
    Insulin glargine + insulin glulisine

    Patients will be randomized to be treated with insulin glargine + insulin glulisine for 24 weeks.

    Drug: Insulin Glargine · Drug: Insulin glulisine

  • Experimental
    Insulin Glargine + Human insulin

    Patients will be randomized to be treated with insulin glargine + human insulin for 24 weeks.

    Drug: human insulin · Drug: Insulin Glargine

Interventions

  • Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.

    Also known as: Insuman Basal

  • Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL. human insulin: bolus injections before each main meal

    Also known as: Insuman Rapid

  • Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.

    Also known as: Lantus

  • Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL. Insulin glulisine: bolus injections before each main meal

    Also known as: Apidra

06

What researchers measure

Primary outcomes

  1. Fasting Intact Proinsulin

    The difference of fasting intact proinsulin after 24 weeks of treatment compared to baseline.

    Time frame: Change from baseline at 24 weeks

Secondary outcomes

  1. Weight

    To evaluate the changes of weight after 24 weeks of treatment compared to baseline.

    Time frame: Baseline and after 24 weeks of treatment.

  2. hsCRP

    To evaluate changes of hsCRP after 24 weeks of treatment compared to baseline.

    Time frame: Baseline and after 24 weeks of treatment.

  3. Adiponectin

    To evaluate changes of adiponectin after 24 weeks of treatment compared to baseline.

    Time frame: Baseline and after 24 weeks of treatment.

  4. MMP-9

    To evaluate changes of MMP-9 after 24 weeks of treatment compared to baseline.

    Time frame: Baseline and after 24 weeks of treatment.

  5. OGTT parameters (insulin, intact proinsulin, glucose at time point 0, 60 and 120 minutes after 24 weeks

    To evaluate changes of OGTT parameters (insulin, intact proinsulin, glucose at time point 0, 60 and 120 minutes) after 24 weeks of treatment compared to baseline.

    Time frame: Baseline and after 24 weeks of treatment.

  6. HOMA-IR score

    To evaluate changes of HOMA-IR score after 24 weeks of treatment compared to baseline.

    Time frame: Baseline and after 24 weeks of treatment.

  7. HbA1c

    To evaluate changes of HbA1C after 24 weeks of treatment compared to baseline.

    Time frame: Baseline and after 24 weeks of treatment.

  8. Weight

    To evaluate changes of weight after 12 weeks of treatment compared to baseline and compared to 24 weeks.

    Time frame: After 12 weeks of treatment compared to baseline and to 24 weeks of treatment.

  9. hsCRP

    To evaluate changes of hsCRP after 12 weeks of treatment compared to baseline and compared to 24 weeks.

    Time frame: After 12 weeks of treatment compared to baseline and to 24 weeks of treatment.

  10. Adiponectin

    To evaluate changes of adiponectin after 12 weeks of treatment compared to baseline and compared to 24 weeks.

    Time frame: After 12 weeks of treatment compared to baseline and to 24 weeks of treatment.

  11. Fasting intact Proinsulin

    To evaluate changes of fasting intact proinsulin after 12 weeks of treatment compared to baseline and compared to 24 weeks.

    Time frame: After 12 weeks of treatment compared to baseline and to 24 weeks of treatment.

  12. Glucose

    To evaluate changes of Glucose after 12 weeks of treatment compared to baseline and compared to 24 weeks.

    Time frame: After 12 weeks of treatment compared to baseline and to 24 weeks of treatment.

  13. HbA1c

    To evaluate changes of HbA1c after 12 weeks of treatment compared to baseline and compared to 24 weeks.

    Time frame: After 12 weeks of treatment compared to baseline and to 24 weeks of treatment.

  14. Responder rate

    To investigate the number of patients with normal values for parameters hsCRP, adiponectin, and intact proinsulin after 24 weeks of treatment (responder rates).

    Time frame: After 24 weeks of treatment compared to baseline.

  15. Hypoglycemic events.

    Hypoglycemic events defined as blood glucose below 63 mg/dl.

    Time frame: Baseline up to 24 weeks.

07

Study locations

1 of 1 sites recruiting
  • ikfe GmbH
    Mainz, Rheinland-Pfalz 55116, Germany
    Recruiting
    • Thomas Forst, MD · Contactthomasf@ikfe.de · +49(0) 6131-576 36 -40
    • Daniela Sachsenheimer, MD · Contactdanielas@ikfe.de · +49(0) 6131-576 36 40
    • Daniela Sachsenheimer, MD · Sub investigator
    • Stephanie Helleberg, MD · Sub investigator
    • Stephan Diessel · Sub investigator
08

References and documents

Publications

  • Semlitsch T, Engler J, Siebenhofer A, Jeitler K, Berghold A, Horvath K. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2020 Nov 9;11(11):CD005613. doi: 10.1002/14651858.CD005613.pub4. PubMed 33166419 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2011
First posted
Dec 29, 2011
Start
Oct 2011
Primary completionEst.
Oct 2012
CompletionEst.
Oct 2012
Last update
Dec 29, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01500850
Lead sponsor
ikfe-CRO GmbH
Collaborators
IKFE Institute for Clinical Research and Development
Responsible party
Sponsor
First posted
Dec 29, 2011
Start date
Oct 2011
Primary completion
Oct 2012 (estimated)
Completion
Oct 2012 (estimated)
Last update
Dec 29, 2011

Study contacts

Andreas Pfützner, Professor
Contact
andreasp@ikfe.de
00496131-57636-0 ext. 20
Thomas Forst, Professor
Contact
thomasf@ikfe.de
00496131-57636-0 ext. 16
Andreas Pfützner, Professor
principal investigator · Ikfe GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin, Regular, Human · Insulin Glargine · Insulin glulisine

Start the discussion